Vietnam To Import GSK Antiviral As Cautionary Move Against H1N1 Flu
This article was originally published in PharmAsia News
Executive Summary
Vietnam authorities have decided to import GlaxoSmithKline's Relenza (zanamivir) for treating the H1N1 flu virus. The purchase of the Australia-developed drug is intended to provide an alternative to Roche's Tamiflu (oseltamivir). A deputy health minister said the price of the drug had not been determined, but the ministry was discussing the matter with GSK. The purchase is being made as a preventative measure, since the more Tamiflu is used, the greater the resistance to it. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.